arrow
Return

Glaucoma: now and beyond

delete2023-11-01
delete82
PRE
AI
H
Hari Jayaram
M
Miriam Kolko
D
David S. Friedman
G
Gus Gazzard *
DOI:10.1016/S0140-6736(23)01289-8delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery. Although modern surgical innovations aim to be less invasive, many have been introduced with little supporting evidence from randomised controlled trials. Many cases remain undiagnosed until the advanced stages of disease due to the limitations of screening and poor access to opportunistic case finding. Future research aims to generate evidence for intraocular pressure-independent neuroprotective treatments, personalised treatment through genetic risk profiling, and exploration of potential advanced cellular and gene therapies.
Keywords:
OPEN-ANGLE GLAUCOMA
OPTIC-NERVE HEAD
SELECTIVE LASER TRABECULOPLASTY
ELEVATED INTRAOCULAR-PRESSURE
GENOME-WIDE ASSOCIATION
VISUAL-FIELD
RISK-FACTORS
SUSCEPTIBILITY LOCI
PIGMENT DISPERSION
RAT MODEL

Journal

The Lancet cover
The Lancet
IF:
88.5
Papers:
5.4W
Citations:
34.8W

Organization

R
Rigshospitalet
Scholars:
1.7W
Papers: 1.3W
Citations: 2.1W
U
university of london
Scholars:
21.3W
Papers: 19.6W
Citations: 305